Levetiracetam suppresses neuronal network dysfunction and reverses synaptic and cognitive deficits in an Alzheimer's disease model.
about
Emerging Link between Alzheimer's Disease and Homeostatic Synaptic PlasticityDissecting Alzheimer disease in Down syndrome using mouse modelsGene expression parallels synaptic excitability and plasticity changes in Alzheimer's diseasePost-traumatic epilepsy: current and emerging treatment optionsDrug development in Alzheimer's disease: the path to 2025Drug repositioning approaches for the discovery of new therapeutics for Alzheimer's diseaseNeuregulin 1 improves cognitive deficits and neuropathology in an Alzheimer's disease model.Cross-species translation of the Morris maze for Alzheimer's disease.Interictal spikes during sleep are an early defect in the Tg2576 mouse model of β-amyloid neuropathologySynaptic Vesicle Glycoprotein 2A Ligands in the Treatment of Epilepsy and BeyondStem cell therapy for Alzheimer's disease and related disorders: current status and future perspectivesAnalyzing dendritic spine pathology in Alzheimer's disease: problems and opportunitiesElevation of brain magnesium prevents synaptic loss and reverses cognitive deficits in Alzheimer's disease mouse model.Na, K-ATPase α3 is a death target of Alzheimer patient amyloid-β assembly.Physiologic brain activity causes DNA double-strand breaks in neurons, with exacerbation by amyloid-βSeizures and epileptiform activity in the early stages of Alzheimer diseaseReducing hippocampal extracellular matrix reverses early memory deficits in a mouse model of Alzheimer's disease.Caloric restriction protects against electrical kindling of the amygdala by inhibiting the mTOR signaling pathway.Brivaracetam, but not ethosuximide, reverses memory impairments in an Alzheimer's disease mouse model.Spatial learning and memory impairments are associated with increased neuronal activity in 5XFAD mouse as measured by manganese-enhanced magnetic resonance imaging.Suppression of InsP3 receptor-mediated Ca2+ signaling alleviates mutant presenilin-linked familial Alzheimer's disease pathogenesis.Phosphorylation of tau at Y18, but not tau-fyn binding, is required for tau to modulate NMDA receptor-dependent excitotoxicity in primary neuronal culture.Notoginsenoside R1 increases neuronal excitability and ameliorates synaptic and memory dysfunction following amyloid elevation.p38 MAP kinase-mediated NMDA receptor-dependent suppression of hippocampal hypersynchronicity in a mouse model of Alzheimer's diseaseLife extension factor klotho prevents mortality and enhances cognition in hAPP transgenic mice.Oligomeric Aβ-induced synaptic dysfunction in Alzheimer's disease.More than cholesterol transporters: lipoprotein receptors in CNS function and neurodegenerationThe human synaptic vesicle protein, SV2A, functions as a galactose transporter in Saccharomyces cerevisiae.Altered neurotransmission in the lateral amygdala in aged human apoE4 targeted replacement mice.Tau reduction diminishes spatial learning and memory deficits after mild repetitive traumatic brain injury in mice.P301L tau expression affects glutamate release and clearance in the hippocampal trisynaptic pathway.Tau aggregation and its interplay with amyloid-β.Behaviorally activated mRNA expression profiles produce signatures of learning and enhanced inhibition in aged rats with preserved memory.Tau reduction prevents disease in a mouse model of Dravet syndromeEarly onset of hypersynchronous network activity and expression of a marker of chronic seizures in the Tg2576 mouse model of Alzheimer's disease.Impaired firing properties of dentate granule neurons in an Alzheimer's disease animal model are rescued by PPARγ agonism.Sleep interacts with aβ to modulate intrinsic neuronal excitabilityRegional and sub-regional differences in hippocampal GABAergic neuronal vulnerability in the TgCRND8 mouse model of Alzheimer's disease.A novel triple repeat mutant tau transgenic model that mimics aspects of pick's disease and fronto-temporal tauopathies.Response of the medial temporal lobe network in amnestic mild cognitive impairment to therapeutic intervention assessed by fMRI and memory task performance
P2860
Q26750576-E0ED7BF5-4400-4BDB-BE26-A24AD3A649DDQ26777254-729D2EEE-F968-4A16-B772-264E9CCCF892Q26785375-3C89F6B9-37F6-42E8-A6AD-0E4218F5112FQ27004055-91803A14-B372-4496-B27F-9570BEC3A22CQ27007748-D9A1642C-17B0-4DE8-844D-076C89D0A6A6Q27024122-0F9C5CC2-AEEF-4F5F-97DD-B5908AD4A33DQ27316651-0DB3DBEA-7619-40FA-A9E7-EF68DAC4CD28Q27332848-D43B35DD-00B2-4248-B688-18D02D73B6F8Q27438189-8AD4FED4-7D09-4B06-A289-3E1B07DDDB99Q28068507-FB177860-CC80-46E6-ACCA-10F4920891B3Q28085612-F0508B1A-3C07-4362-934E-64A19A3A5A57Q28087158-165E99E6-6342-4BDF-97EA-979704526128Q28247764-9E188E9E-A017-42F7-85AE-882915ACB4B7Q28572007-AAC77C23-72AD-4710-8CD6-48A26E164AF9Q30539255-FD0E39FF-8FDC-4611-ABBF-7C784C5C914AQ30577633-9681BBF1-CC44-4645-AD3D-F8AD89FE462BQ30586616-3431FC7F-8CBD-4BDA-B53C-F7986AC6B594Q30626751-5175B666-0F25-4E11-B729-8BD6FA837DF0Q30647611-C90418AA-1BD9-4E6A-ACB6-DEB97D7A0D36Q31122548-063B6F40-6E3F-4EC2-A49C-C68B6C9A21E7Q33605796-71DBF1CC-FBA6-4CF4-8D02-E52386AECB5DQ33709279-6B6FC066-9BB4-4327-A20A-B398C92F4506Q34169539-6566BB5E-C025-4386-BF2F-A3FEC208C511Q34416848-A4C133A5-731D-43F2-9ECC-4FCC077307F8Q34462326-E287697A-4447-48B0-B25E-76E692958C48Q34544243-802CE54B-AFCE-4418-8551-4060D92BCDC7Q34557404-9B854429-D935-4DD6-9B12-24D5A578F2C5Q34580236-5918D516-9F5F-4280-BD30-6AA4A7CE7C03Q34593131-7CB38A97-9D24-476E-A454-B9D161012D8EQ34796105-5E7273BE-A5F0-4B6D-8334-E4035648E53CQ34995948-A3BCCB2C-A070-45BB-8910-7AD7326BAD9DQ35008256-AF0B4569-4776-4BB1-BD02-3CE0115434ACQ35071062-B668638C-C0EA-484A-BB18-02794B9B7D30Q35115219-B52224E9-308F-40B3-8C96-BAF9390CC6E3Q35175125-8AE9AFF2-2B9C-4628-A938-A9C806F0AAE2Q35178508-7F0F2B9F-5849-48FF-A10A-C45744B0110FQ35196370-310B9427-9509-4E03-B847-5903ADC94832Q35212041-93D6EB05-0909-450C-B4C7-CCFEC967EE58Q35213879-EDC6048D-39C5-4F4D-8DF2-1C3F833D1A6DQ35227785-E8424E72-CDDD-49EC-B59F-143F511A068B
P2860
Levetiracetam suppresses neuronal network dysfunction and reverses synaptic and cognitive deficits in an Alzheimer's disease model.
description
2012 nî lūn-bûn
@nan
2012 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Levetiracetam suppresses neuro ...... n an Alzheimer's disease model
@nl
Levetiracetam suppresses neuro ...... an Alzheimer's disease model.
@ast
Levetiracetam suppresses neuro ...... an Alzheimer's disease model.
@en
type
label
Levetiracetam suppresses neuro ...... n an Alzheimer's disease model
@nl
Levetiracetam suppresses neuro ...... an Alzheimer's disease model.
@ast
Levetiracetam suppresses neuro ...... an Alzheimer's disease model.
@en
prefLabel
Levetiracetam suppresses neuro ...... n an Alzheimer's disease model
@nl
Levetiracetam suppresses neuro ...... an Alzheimer's disease model.
@ast
Levetiracetam suppresses neuro ...... an Alzheimer's disease model.
@en
P2093
P2860
P3181
P356
P1476
Levetiracetam suppresses neuro ...... an Alzheimer's disease model.
@en
P2093
Anna G Orr
Gui-Qiu Yu
John R Cirrito
Jorge J Palop
Kaitlyn Ho
Keith A Vossel
Lennart Mucke
Nino Devidze
Pascal E Sanchez
P2860
P304
P3181
P356
10.1073/PNAS.1121081109
P407
P50
P577
2012-08-06T00:00:00Z